The depletion of MEL-18 promoted trastuzumab resistance by increasing ADAM10/17 mediated ErbB ligand production and receptor heterodimerization in HER2 positive breast cancer patients [23]. This evidence concerns the gene ADAM10 and breast carcinoma.